Eli Lilly, Evidation Health expand data analysis collaboration

Eli Lilly and Co., a drug manufacturer, and Evidation Health, a health and behavior measurement company, entered into a multiyear agreement that grants Lilly global access to Evidation's Andromeda data platform.

Per the agreement, Lilly's scientists and researchers will have access to Evidation's data platform, helping them measure and understand patient behavior with regard to their health. They will have access to consented data derived from smartphones, connected sensors, wearables and the patient's own voice.

Lilly's research teams will also be able to use Evidation-built algorithms to process raw data for use in clinical studies or to create predictive models.

"Our initial collaborations with Lilly demonstrated that digital biomarkers can play a significant role in understanding individuals and disease, and we are excited to expand our collaboration," said Christine Lemke, co-founder and president of Evidation.

More articles on health IT:
Teladoc faces class action lawsuit: 8 things to know
Google plans $1B New York City expansion
Vermont community hospital notifies 32,000 after data breach: 4 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers